

**ALKEM LABORATORIES LTD.**

Regd. Office : ALKEM HOUSE, Senapati Bapat Marg,
Lower Parel (West), Mumbai - 400 013, Maharashtra, India.

- Phone: +91-22-3982 9999 • Fax: 022-2495 2955
- Email: contact@alkem.com • Website: www.alkemlabs.com
- CIN: L00305MH1973PLC174201

11th November, 2019

The Corporate Relationship Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai 400 001. <i>Scrip Code: 539523</i>	National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra East, Mumbai 400 051. <i>Scrip Symbol: ALKEM</i>
---	--

Dear Sirs,

Sub: Outcome of Board Meeting held on 11th November, 2019.

In continuation of our letter dated 18th October, 2019 and pursuant to Regulation 30 read with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations") the Board of Directors of the Company, at its meeting held today, i.e. 11th November, 2019, has inter alia: .


1. approved the Standalone and Consolidated Unaudited Financial Results for the quarter and half year ended 30th September, 2019.
2. appointed Mr. Sarvesh Singh (DIN: 01278229) as an Additional Director and as a Whole Time Director designated as Executive Director on the Board of Directors of the Company w.e.f 11th November, 2019.

Accordingly we are enclosing herewith the copy of Standalone and Consolidated Unaudited Financial Results along with the Limited Review Report of the Statutory Auditors of the Company for the quarter and half year ended 30th September, 2019, as required under Regulation 33 of the Listing Regulations.

The meeting of the Board of Directors of the Company commenced at 10.30 A.M and concluded at 2.30 P.M

Kindly take the same on record.

Sincerely,
For **Alkem Laboratories Limited**


Manish Narang
President - Legal, Company Secretary & Compliance Officer
Encl.: a/a

B S R & Co. LLP

Chartered Accountants

5th Floor, Lodha Excelus,
Apollo Mills Compound
N. M. Joshi Marg, Mahalaxmi
Mumbai - 400 011
India

Telephone +91 (22) 4345 5300
Fax +91 (22) 4345 5399

Limited review report

To Board of Directors of Alkem Laboratories Limited

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Alkem Laboratories Limited (“the Parent”) and its subsidiaries (the Parent and its subsidiaries together referred to as “the Group”), for the quarter ended 30 September 2019 and year to date results for the period from 1 April 2019 to 30 September 2019 (“the Statement”), being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (‘Listing Regulations’).
2. This Statement, which is the responsibility of the Parent’s management and approved by the Parent’s Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 “*Interim Financial Reporting*” (“Ind AS 34”), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 “*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*”, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the following entities:

Sr. No.	Name of entity	Relationship
1.	S & B Holdings B.V., Netherlands (S&B Holdings)	Wholly Owned Subsidiary
2.	ThePharmaNetwork, LLC, USA (TPN)	Wholly Owned Subsidiary of S&B Holdings
3.	Ascend Laboratories LLC, USA	Wholly Owned Subsidiary of TPN
4.	S & B Pharma Inc., USA	Wholly Owned Subsidiary
5.	Pharmacor Pty Limited, Australia	Wholly Owned Subsidiary

Limited review report (Continued)**Alkem Laboratories Limited**

Sr. No.	Name of entity	Relationship
6.	Alkem Laboratories (NIG) Limited, Nigeria	Wholly Owned Subsidiary (Upto 6 May 2018)
7.	Alkem Laboratories (PTY) Ltd, South Africa	Wholly Owned Subsidiary
8.	Enzene Biosciences Ltd, India	Wholly Owned Subsidiary
9.	Cachet Pharmaceuticals Pvt Ltd, India	Subsidiary
10.	Indchemie Health Specialities Pvt Ltd, India	Subsidiary
11.	Alkem Laboratories Corporation, Philippines	Wholly Owned Subsidiary
12.	Ascend GmbH, Germany	Wholly Owned Subsidiary
13.	Ascend Laboratories SDN BHD., Malaysia	Wholly Owned Subsidiary
14.	Ascend Laboratories SpA, Chile (Ascend Chile)	Wholly Owned Subsidiary
15.	Pharma Network SpA, Chile	Wholly Owned Subsidiary of Ascend Chile
16.	Alkem Laboratories Korea Inc, Korea	Wholly Owned Subsidiary
17.	Pharmacor Ltd., Kenya	Wholly Owned Subsidiary
18.	The PharmaNetwork, LLP, Kazakhstan	Wholly Owned Subsidiary
19.	Ascend Laboratories (UK) Ltd., UK	Wholly Owned Subsidiary
20.	Ascend Laboratories Ltd., Canada	Wholly Owned Subsidiary
21.	Alkem Foundation	Wholly Owned Subsidiary
22.	Ascend Laboratories S.A.S, Colombia	Wholly Owned Subsidiary (w.e.f. 4 June 2019)

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. We did not review the interim financial statements/ financial information/ financial results of seven subsidiaries included in the Statement, whose interim financial statements/ financial information/ financial results reflect total assets of Rs 16,316.3 million as at 30 September 2019 and total revenues of Rs 3,662.0 million and Rs. 6,585.8 million, total net loss after tax of Rs. 331.5 million and Rs 617.6 million and total comprehensive income of Rs (325.9) million and Rs (632.9) million, for the quarter ended 30 September 2019 and for the period from 1 April 2019 to 30 September 2019, respectively, and cash flows (net) of Rs 364.0 million for the period from 1 April 2019 to 30 September 2019, as considered in the consolidated unaudited financial results. These interim financial statements/ financial information/ financial results have been reviewed by other auditors whose reports have been furnished to us and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement is not modified in respect of the above matters.



Limited review report (*Continued*)

Alkem Laboratories Limited

7. The Statement includes the interim financial statements/ financial information/ financial results of twelve subsidiaries which have not been reviewed, whose interim financial statements/ financial information/ financial results reflect total assets of Rs. 3,372.4 million as at 30 September 2019 and total revenue of Rs. 209.9 million and Rs. 407.2 million, total net loss after tax of Rs. 68.9 million and Rs. 145.5 million and total comprehensive income of Rs. (45.4) million and Rs. (133.1) million for the quarter ended 30 September 2019 and for the period from 1 April 2019 to 30 September 2019, respectively, and cash flows (net) of Rs. 10.9 for the period from 1 April 2019 to 30 September 2019, as considered in the Statement. According to the information and explanations given to us by the management, these interim financial statements/ financial information/ financial results are not material to the Group.

Our conclusion on the Statement is not modified in respect of the above matter

For **B S R & Co. LLP**

Chartered Accountants

Firm's Registration No: 101248W/W-100022



Sadashiv Shetty

Partner

Membership No: 048648

UDIN: 19048648AAAACO5689

Mumbai
11 November 2019

ALKEM LABORATORIES LIMITED

CIN No :L00305MH1973PLC174201

Regd. Office and Corporate Office: Alkem House, Senapati Bapat Marg, Lower Parel, Mumbai - 400013, Maharashtra, India

Tel No:91 22 3982 9999 Fax No: +91 22 2492 7190

Website : www.alkemlabs.com, Email Id : investors@alkem.com

Statement of Unaudited Consolidated Financial Results for the Quarter and Six months ended 30 September 2019

(₹ in Million except per share data)

Particulars	Quarter ended			Six months ended		Year ended
	30.09.2019 Unaudited	30.06.2019 Unaudited	30.09.2018 Unaudited	30.09.2019 Unaudited	30.09.2018 Unaudited	31.03.2019 Audited
1 Income						
(a) Revenue from operations	22,640.3	18,495.0	19,189.0	41,135.3	35,778.4	73,571.9
(b) Other income	314.2	174.7	245.2	488.9	512.9	877.0
Total Income	22,954.5	18,669.7	19,434.2	41,624.2	36,291.3	74,448.9
2 Expenses						
(a) Cost of materials consumed	5,284.7	5,453.7	4,484.2	10,738.4	8,323.3	18,111.4
(b) Purchases of stock-in-trade	3,668.2	3,443.9	2,167.8	7,112.1	4,943.8	11,301.9
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	90.1	(1,779.4)	758.2	(1,689.3)	447.0	36.4
(d) Employee benefits expense	3,896.3	3,903.2	3,278.6	7,799.5	6,673.1	13,624.6
(e) Finance costs	177.5	161.2	164.0	338.7	326.6	546.3
(f) Depreciation and amortisation expense	564.0	558.3	457.7	1,122.3	882.2	1,931.8
(g) Other expenses	5,175.1	4,828.6	4,863.5	10,003.7	9,717.4	19,349.9
Total Expenses	18,855.9	16,569.5	16,174.0	35,425.4	31,313.4	64,902.3
3 Profit before exceptional items and tax (1) - (2)	4,098.6	2,100.2	3,260.2	6,198.8	4,977.9	9,546.6
4 Exceptional items	-	-	-	-	-	-
5 Profit before tax (3) - (4)	4,098.6	2,100.2	3,260.2	6,198.8	4,977.9	9,546.6
6 Tax expense / (credit)						
Current tax	776.5	634.8	702.5	1,411.3	1,098.3	2,291.7
Deferred tax	(483.1)	(407.5)	(46.5)	(890.6)	(97.3)	(481.5)
Total Tax Expense	293.4	227.3	656.0	520.7	1,001.0	1,810.2
7 Profit for the period (5) - (6)	3,805.2	1,872.9	2,604.2	5,678.1	3,976.9	7,736.4
8 Other Comprehensive Income (net of tax)						
Items that will not be reclassified to profit or loss	(20.8)	(12.6)	1.5	(33.4)	12.4	(69.4)
Income tax relating to items that will not be reclassified to profit or loss	6.3	3.3	(1.0)	9.6	(4.6)	23.7
Items that will be reclassified to profit or loss	101.4	(131.4)	436.5	(30.0)	716.0	355.7
Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
Total Other Comprehensive Income (net of tax)	86.9	(140.7)	437.0	(53.8)	723.8	310.0
9 Total Comprehensive Income for the period (comprising Profit for the period (after tax) and Other Comprehensive Income (net of tax)) (7) + (8)	3,892.1	1,732.2	3,041.2	5,624.3	4,700.7	8,046.4
10 Profit attributable to						
a) Owners of the Company	3,708.5	1,854.7	2,544.7	5,563.2	3,906.2	7,605.1
b) Non-Controlling Interest	96.7	18.2	59.5	114.9	70.7	131.3
11 Other Comprehensive Income attributable to						
a) Owners of the Company	91.9	(138.2)	437.0	(46.3)	721.5	311.1
b) Non-Controlling Interest	(5.0)	(2.5)	-	(7.5)	2.3	(1.1)
12 Total Comprehensive Income attributable to						
a) Owners of the Company	3,800.4	1,716.5	2,981.7	5,516.9	4,627.7	7,916.2
b) Non-Controlling Interest	91.7	15.7	59.5	107.4	73.0	130.2
13 Paid-up Equity Share Capital (Face Value ₹ 2 each fully paid up)	239.1	239.1	239.1	239.1	239.1	239.1
14 Other Equity						54,154.3
15 Earnings Per Share of ₹2 each (not annualised for the quarters)						
(a) ₹ (Basic)	31.02	15.51	21.28	46.53	32.67	63.61
(b) ₹ (Diluted)	31.02	15.51	21.28	46.53	32.67	63.61



Binu Aund



Consolidated Statement of Assets and Liabilities as at 30 September 2019

Particulars	As at 30 September 2019 (Unaudited)	As at 31 March 2019 (Audited)
I. ASSETS		
1 Non-current assets		
(a) Property, plant and equipment	20,612.2	21,056.2
(b) Capital work-in-progress	5,770.8	4,929.6
(c) Goodwill	236.4	231.5
(d) Other Intangible assets	1,379.4	442.6
(e) Goodwill on consolidation	3,597.3	3,574.1
(f) Financial Assets		
(i) Investments	988.2	957.4
(ii) Loans	115.2	136.3
(iii) Others financial assets	879.0	462.0
(g) Deferred tax assets (net)	7,977.7	7,076.3
(h) Non current tax assets (net)	156.5	392.7
(i) Other non-current assets	741.9	661.9
Total Non-current assets	42,454.6	39,920.6
2 Current assets		
(a) Inventories	16,210.5	14,998.7
(b) Financial Assets		
(i) Investments	2,159.8	2,278.8
(ii) Trade receivables	14,286.4	12,484.1
(iii) Cash and cash equivalents	3,070.5	2,490.5
(iv) Bank balances other than (iii) above	6,554.8	4,125.5
(v) Loans	313.7	308.0
(vi) Others financial assets	1,516.5	1,064.6
(c) Other current assets	4,859.3	4,293.8
(d) Non-current assets held for sale	118.2	117.3
Total Current assets	49,089.7	42,161.3
TOTAL ASSETS	91,544.3	82,081.9
II. EQUITY AND LIABILITIES		
1 Equity		
(a) Equity share capital	239.1	239.1
(b) Other Equity	58,514.0	54,154.3
Equity attributable to owners of the Company	58,753.1	54,393.4
(c) Non-controlling interest	1,409.2	1,326.1
Total Equity	60,162.3	55,719.5
2 Non-current liabilities		
(a) Financial Liabilities		
(i) Borrowings	3,336.9	2,313.0
(b) Provisions	2,315.3	2,010.3
(c) Deferred tax liabilities (Net)	-	3.0
(d) Other non-current liabilities	88.1	133.9
Total Non-Current liabilities	5,740.3	4,460.2
3 Current liabilities		
(a) Financial Liabilities		
(i) Borrowings	10,802.6	6,712.7
(ii) Trade payables		
Dues of Micro and Small Enterprises	900.7	606.3
Dues of Creditors other than Micro and Small Enterprises	6,637.7	9,016.2
(iii) Other financial liabilities	5,078.8	3,428.7
(b) Other current liabilities	808.5	852.1
(c) Provisions	1,371.7	1,265.1
(d) Current tax Liabilities (Net)	41.7	21.1
Total Current liabilities	25,641.7	21,902.2
TOTAL EQUITY AND LIABILITIES	91,544.3	82,081.9



Notes :

- 1 The above unaudited consolidated financial results of the Company were reviewed and recommended by the Audit Committee and subsequently approved by the Board of Directors at its meeting held on 11 November 2019. The figures for the quarter and six months ended 30 September 2019 have been subjected to limited review by the statutory auditors. The auditors have expressed an unmodified opinion on the financial results for the quarter and six months ended 30 September 2019.
- 2 Effective 1 April 2019, the Group has adopted Ind AS 116 "Leases" applicable to all contracts having lease components existing on 1 April 2019 using modified retrospective approach. This has resulted in recognising right of use asset and a corresponding lease liability of **Rs.947.2 million** as at 1 April 2019. In the statement of profit and loss for the current period, operating lease expenses has changed from lease rent to depreciation cost for the right of use asset and finance cost for interest accrued on lease liability. Due to this change, profit before tax for the quarter and six months ended 30 September 2019 is lower by **Rs.6.3 million and Rs.11.9 million** respectively. Consequent to adoption of Ind AS 116, there is no impact on retained earnings as on 1 April 2019 resulting in no restatement in results of comparative period.
- 3 Pursuant to the Taxation Law (Amendment) Ordinance, 2019 ('Ordinance') issued by Ministry of Law and Justice (Legislative Department) on 20 September 2019 which is effective 1 April 2019, domestic companies have the option to pay corporate income tax rate at 22% plus applicable surcharge and cess subject to certain conditions. The Company and its subsidiaries incorporated in India have made an assessment of the impact of the Ordinance and decided to continue with the existing tax structure until utilisation of accumulated minimum alternative tax (MAT) credit.
- 4 The Board of Directors at its meeting held on 30 May 2019 had recommended a final dividend of ₹ 8 (Rupees eight only) per equity share (400.0 % on the face value of ₹ 2 each) for the financial year 2018-19 which was paid during the quarter ended 30 September 2019.
- 5 The Group operates in one reportable business segment i.e. "Pharmaceuticals", accordingly no separate disclosure of segment has been made.

BN A



Statement of Consolidated Cash Flow for the six months ended 30 September 2019

(₹ in million)

Particulars	For six months ended 30 September 2019 (Unaudited)	For six months ended 30 September 2018 (Unaudited)
A Cash Flow from Operating Activities:		
Profit before Tax	6,198.8	4,977.9
<u>Adjustments for:</u>		
Depreciation and amortisation expense	1,122.3	882.2
Profit on sale of investments	(0.5)	(42.7)
Unrealised (Profit) / loss on fair valuation of investments (net)	(15.8)	2.8
(Profit) / Loss on sale of property, plant and equipment (net)	(19.8)	5.6
Employee stock compensation expenses	1.4	1.8
Unrealised foreign currency loss on revaluation (net)	171.7	218.9
Dividend Income	(0.8)	(0.1)
Impairment loss on property, plant and equipment	34.0	-
Interest Income	(262.7)	(185.2)
Interest expenses	338.7	326.6
Allowances for doubtful debts	-	94.1
Rent income	(2.7)	(2.7)
Subtotal of Adjustments	1,365.8	1,301.3
Operating profit before working capital changes	7,564.6	6,279.2
Changes in working capital:		
Increase in trade receivables	(1,734.7)	(1,686.9)
(Increase) in loans, other financial assets and other assets	(718.6)	(204.6)
(Increase) / Decrease in inventories	(1,203.4)	401.6
Decrease in trade payable, other financial liabilities and other liabilities	(934.6)	(2,726.3)
Increase in provisions	381.0	267.6
Subtotal of adjustments	(4,210.3)	(3,948.6)
Cash generated from operations	3,354.3	2,330.6
Less: Income taxes paid (net of refund)	(1,201.6)	(1,159.6)
Net Cash generated from operating activities	2,152.7	1,171.0
B Cash Flow from Investing Activities:		
Purchases of property, plant and equipment	(1,768.9)	(3,478.0)
Sale of property, plant and equipment	93.9	5.8
Proceeds from sale of investments (net)	111.8	1,061.6
(Investment) in / Redemption of bank deposits having maturity of more than 3 months	(2,870.6)	1,545.5
Dividend received	0.8	0.1
Interest received	268.3	272.9
Rent received	2.7	2.7
Net cash (used in) investing activities	(4,162.0)	(589.4)
C Cash Flow from Financing Activities:		
Proceeds from non-current borrowings (net)	641.5	418.7
Proceeds from / (Repayment) of current borrowings (net)	3,571.6	(48.7)
Repayment of lease liabilities	(91.9)	-
Dividends and corporate dividend tax paid	(1,182.7)	(1,036.8)
Interest and bank charges paid	(338.6)	(325.2)
Net cash (used in)/generated from financing activities	2,599.9	(992.0)
D Net (decrease)/increase in Cash and Cash Equivalents (A+B+C)	590.6	(410.5)
E Cash & Cash Equivalents as at the beginning of the period	2,490.5	1,667.1
Add/Less: Effect of exchange difference on foreign currency cash and cash equivalents	(10.6)	77.1
F Cash & Cash Equivalents as at the end of the period (D+E)	3,070.5	1,333.8

Notes:

- The above Cash Flow Statement has been prepared under the "Indirect Method" as set out in the Indian Accounting Standard (Ind AS-7) - "Statement of Cash Flows"
- Purchase of Property, Plant and Equipment includes movements of capital work-in-progress (including capital advances) during the period.



Place: Mumbai
Date: 11 November 2019

By Order of the Board
For Alkem Laboratories Limited

B.N. Singh

B.N. Singh
Executive Chairman
DIN: 00760310



B S R & Co. LLP

Chartered Accountants

5th Floor, Lodha Excelus,
Apollo Mills Compound
N. M. Joshi Marg, Mahalaxmi
Mumbai - 400 011
India

Telephone +91 (22) 4345 5300
Fax +91 (22) 4345 5399

Limited review report

To Board of Directors of Alkem Laboratories Limited

1. We have reviewed the accompanying Statement of unaudited standalone financial results of Alkem Laboratories Limited ('the Company') for the quarter ended and year to date results for the period from 1 April 2019 to 30 September 2019 ('the Statement').
2. This Statement, which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "*Interim Financial Reporting*" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For B S R & Co. LLP
Chartered Accountants

Firm's Registration No: 101248W/W-100022



Sadashiv Shetty
Partner

Mumbai
11 November 2019

Membership No: 048648
UDIN: 19048648AAAACN8608

ALKEM LABORATORIES LIMITED

CIN No.:L00305MH1973PLC174201

Regd. Office and Corporate Office: Alkem House, Senapati Bapat Marg, Lower Parel, Mumbai - 400013, Maharashtra, India.

Tel No:91 22 3982 9999 Fax No: +91 22 2492 7190

Website : www.alkemlabs.com, Email Id : investors@alkem.com

Statement of Unaudited Standalone Financial Results for the Quarter and Six months ended 30 September 2019

(₹ in Million except per share data)

Particulars	Quarter ended			Six months ended		Year ended
	30.09.2019 Unaudited	30.06.2019 Unaudited	30.09.2018 Unaudited	30.09.2019 Unaudited	30.09.2018 Unaudited	31.03.2019 Audited
1 Income						
(a) Revenue from operations	18,946.5	14,985.1	14,402.0	33,931.6	27,101.0	57,140.9
(b) Other income	305.9	127.2	239.3	433.1	433.6	675.8
Total Income	19,252.4	15,112.3	14,641.3	34,364.7	27,534.6	57,816.7
2 Expenses						
(a) Cost of materials consumed	4,414.3	4,633.7	3,710.5	9,048.0	6,747.5	14,972.2
(b) Purchases of stock-in-trade	2,177.0	2,017.0	1,261.6	4,194.0	3,157.9	6,880.9
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	839.3	(937.6)	568.2	(98.3)	579.4	865.6
(d) Employee benefits expense	2,755.0	2,835.8	2,283.5	5,590.8	4,711.1	9,600.9
(e) Finance costs	101.0	91.5	89.4	192.5	193.6	282.6
(f) Depreciation and amortisation expense	402.5	401.3	333.7	803.8	649.8	1,410.7
(g) Other expenses	3,910.4	3,785.0	3,546.7	7,695.4	7,071.4	14,364.2
Total Expenses	14,599.5	12,826.7	11,793.6	27,426.2	23,110.7	48,377.1
3 Profit before exceptional item and tax (1) - (2)	4,652.9	2,285.6	2,847.7	6,938.5	4,423.9	9,439.6
4 Exceptional item	-	-	-	-	-	-
5 Profit before tax (3) - (4)	4,652.9	2,285.6	2,847.7	6,938.5	4,423.9	9,439.6
6 Tax expense / (credit)						
Current tax	720.2	532.3	620.3	1,252.5	960.3	2,004.1
Deferred tax	(407.5)	(352.9)	(155.6)	(760.4)	(214.3)	(562.9)
Total Tax Expense	312.7	179.4	464.7	492.1	746.0	1,441.2
7 Profit for the period after tax (5 - 6)	4,340.2	2,106.2	2,383.0	6,446.4	3,677.9	7,998.4
8 Other Comprehensive Income (net of tax)						
Items that will not be reclassified to profit or loss	(5.9)	(5.8)	3.1	(11.7)	6.2	(64.3)
Income tax relating to items that will not be reclassified to profit or loss	2.1	2.0	(1.0)	4.1	(2.1)	22.5
Items that will be reclassified to profit or loss	-	-	-	-	-	-
Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
Total Other Comprehensive Income (net of tax)	(3.8)	(3.8)	2.1	(7.6)	4.1	(41.8)
9 Total Comprehensive Income for the period (comprising Profit for the period (after tax) and Other Comprehensive Income (net of tax)) (7) + (8)	4,336.4	2,102.4	2,385.1	6,438.8	3,682.0	7,956.6
10 Paid-up Equity Share Capital (Face Value ₹ 2 each fully paid up)	239.1	239.1	239.1	239.1	239.1	239.1
11 Other Equity						54,413.0
12 Earnings Per Share of ₹ 2 each (not annualised for the quarters)						
(a) ₹ (Basic)	36.30	17.62	19.93	53.92	30.76	66.90
(b) ₹ (Diluted)	36.30	17.62	19.93	53.92	30.76	66.90



BN A...



Statement of Assets and Liabilities as at 30 September 2019

(₹ in Million)

Particulars	As at 30 September 2019 (Unaudited)	As at 31 March 2019 (Audited)
I. ASSETS		
1 Non-current assets		
(a) Property, plant and equipment	15,535.2	15,737.6
(b) Capital work-in-progress	4,131.2	3,815.9
(c) Intangible assets	986.2	326.2
(d) Investment in subsidiaries	14,329.6	13,821.7
(e) Financial Assets		
(i) Investments	958.0	942.5
(ii) Loans	316.7	127.3
(iii) Others financial assets	776.2	161.2
(f) Deferred tax assets (net)	7,130.2	6,365.9
(g) Non current tax assets (net)	60.0	262.3
(h) Other non-current assets	848.8	554.1
Total Non-current assets	45,072.1	42,114.7
2 Current assets		
(a) Inventories	9,682.5	9,912.8
(b) Financial Assets		
(i) Investments	2,070.4	2,191.8
(ii) Trade receivables	12,697.9	9,666.4
(iii) Cash and cash equivalents	1,865.6	1,614.4
(iv) Bank balances other than (iii) above	4,564.5	2,365.0
(v) Loans	263.5	262.5
(vi) Others financial assets	1,426.4	1,010.4
(c) Other current assets	4,099.5	3,603.8
(d) Non-current assets held for sale	124.1	179.7
Total Current assets	36,794.4	30,806.8
TOTAL ASSETS	81,866.5	72,921.5
II. EQUITY AND LIABILITIES		
1 Equity		
(a) Equity share capital	239.1	239.1
(b) Other Equity	59,703.9	54,413.0
Total Equity	59,943.0	54,652.1
2 Non-current liabilities		
(a) Financial Liabilities		
(i) Borrowings	596.2	63.2
(b) Provisions	1,931.5	1,688.3
(c) Other non-current liabilities	86.7	92.3
Total Non-Current liabilities	2,614.4	1,843.8
3 Current liabilities		
(a) Financial Liabilities		
(i) Borrowings	7,609.6	4,966.4
(ii) Trade payables		
Dues of Micro and Small Enterprises	677.6	346.8
Dues of creditors other than Micro and Small Enterprises	5,609.5	7,194.1
(iii) Other financial liabilities	3,600.3	2,131.6
(b) Other current liabilities	704.3	742.0
(c) Provisions	1,107.8	1,037.8
(d) Current tax Liabilities (Net)	-	6.9
Total Current liabilities	19,309.1	16,425.6
TOTAL EQUITY AND LIABILITIES	81,866.5	72,921.5



Notes :

- 1 The above unaudited standalone financial results of the Company were reviewed and recommended by the Audit Committee and subsequently approved by the Board of Directors at its meeting held on 11 November 2019. The figures for the quarter and six months ended 30 September 2019 have been subjected to limited review by the statutory auditors. The auditors have expressed an unmodified opinion on the financial results for the quarter and six months ended 30 September 2019.
- 2 Effective 1 April 2019, the Company has adopted Ind AS 116 "Leases" applicable to all contracts having lease components existing on 1 April 2019 using modified retrospective approach. This has resulted in recognising right of use asset and a corresponding lease liability of **Rs.646.2 million** as at 1 April 2019. In the statement of profit and loss for the current period, operating lease expenses has changed from lease rent to depreciation cost for the right of use asset and finance cost for interest accrued on lease liability. Due to this change, profit before tax for the quarter and six months ended 30 September 2019 is lower by **Rs.5.8 million** and **Rs.11.2 million** respectively. Consequent to adoption of Ind AS 116, there is no impact on retained earnings as on 1 April 2019 resulting in no restatement in results of comparative period.
- 3 Pursuant to the Taxation Law (Amendment) Ordinance, 2019 ('Ordinance') issued by Ministry of Law and Justice (Legislative Department) on 20 September 2019 which is effective 1 April 2019, domestic companies have the option to pay corporate income tax rate at 22% plus applicable surcharge and cess subject to certain conditions. The Company has made an assessment of the impact of the Ordinance and decided to continue with the existing tax structure until utilisation of accumulated minimum alternative tax (MAT) credit.
- 4 On 15 October 2019, the Company has acquired an industrial undertaking having facility of manufacturing liquid and food products, on a going concern basis from Cachet Pharmaceuticals Private Limited, a subsidiary of the Company for a total consideration of **Rs.518.5 million**.
- 5 The Board of Directors at its meeting held on 30 May 2019 had recommended a final dividend of ₹ 8 (Rupees eight only) per equity share (400.0 % on the face value of ₹ 2 each) for the financial year 2018-19 which was paid during the quarter ended 30 September 2019.
- 6 The Company operates in one reportable business segment i.e. "Pharmaceuticals", accordingly no separate disclosure of segment has been made.



Statement of Cash Flow for the six months ended 30 September 2019

(₹ in Million)

Particulars	For six months ended 30 September 2019 (Unaudited)	For six months ended 30 September 2018 (Unaudited)
A Cash Flow from Operating Activities:		
Profit before tax	6,938.5	4,423.9
<u>Adjustments for:</u>		
Depreciation and amortisation	803.8	649.8
Fair valuation of investments	(20.9)	-
Profit on sale of investments (net)	-	(42.6)
(Profit)/Loss on sale of property, plant and equipment (net)	(40.3)	4.8
Dividend income	(26.1)	(20.5)
Interest income	(201.6)	(145.3)
Interest expenses	192.5	193.6
Allowances for doubtful debts	(9.3)	70.3
Unrealised foreign currency loss on revaluation (net)	178.4	143.4
Rent income	(10.1)	(10.0)
Subtotal of Adjustments	866.4	843.5
Operating profit before working capital changes	7,804.9	5,267.4
Changes in working capital:		
Adjustments for (increase)/decrease in:		
Increase in trade receivables	(3,022.2)	(646.5)
(Increase) / Decrease in loans, other financial assets and other assets	(1,104.3)	316.5
Decrease in inventories	230.3	298.2
increase / (Decrease) in trade payable, other financial liabilities and other liabilities	52.1	(2,729.1)
Increase in provisions	301.6	298.9
Subtotal of Adjustments	(3,542.5)	(2,462.0)
Cash generated from operations	4,262.4	2,805.4
Less: Income taxes paid (net of refund)	(1,056.9)	(955.8)
Net cash generated from operating activities	3,205.5	1,849.6
B Cash Flow from Investing Activities:		
Purchases of property, plant and equipment	(1,140.1)	(2,309.7)
Sale of property, plant and equipment	92.4	3.6
Proceeds from sale of investments (net)	126.9	1,083.8
Investment in subsidiaries	(508.0)	(740.8)
(Investment) in / Redemption of bank deposits having maturity of more than 3 months	(2,838.5)	1,439.4
Dividend received	26.1	20.5
Interest received	207.2	232.3
Rent received	10.1	10.0
Net Cash (used in) investing activities	(4,023.9)	(260.9)
C Cash Flow from Financing Activities:		
Proceeds from / (Repayment) of current borrowings (net)	2,464.8	(170.0)
Repayment of lease liabilities	(54.8)	-
Dividends and corporate dividend tax paid	(1,147.9)	(1,009.0)
Interest paid	(192.5)	(193.6)
Net cash generated / (used in) financing activities	1,069.6	(1,372.6)
D Net increase in cash and cash equivalents (A+B+C)	251.2	216.1
E Cash and cash equivalents as at beginning of the period	1,614.4	51.6
F Cash and cash equivalents as at end of the period (D+E)	1,865.6	267.7

Notes:

- The above Cash Flow Statement has been prepared under the "Indirect Method" as set out in the Indian Accounting Standard (Ind AS-7) - "Statement of Cash Flows"
- Purchase of Property, Plant and Equipment includes movements of capital work-in-progress (including capital advances) during the period

Place: Mumbai
Date: 11 November 2019



By Order of the Board
For Alkem Laboratories Limited

B.N. Singh
Executive Chairman



**ALKEM LABORATORIES LTD.**

Regd. Office : ALKEM HOUSE, Senapati Bapat Marg,
Lower Parel (West), Mumbai - 400 013, Maharashtra, India.

- Phone: +91-22-3982 9999 • Fax: 022-2495 2955
- Email: contact@alkem.com • Website: www.alkemlabs.com
- CIN: L00305MH1973PLC174201

11th November, 2019

The Corporate Relationship Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai 400 001. <i>Scrip Code: 539523</i>	National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra East, Mumbai 400 051. <i>Scrip Symbol: ALKEM</i>
---	--


Dear Sirs,

Sub: Press Release and Analyst Presentation on Q2FY20 Results and H1FY20 Results

With reference to relevant provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith press release and analyst presentation on Q2FY20 and H1FY20 earnings and business updates and the same will be uploaded on the website of the Company.

Kindly take note of the same.

Sincerely,
For **Alkem Laboratories Limited**


Manish Narang
President - Legal, Company Secretary & Compliance Officer

Encl.: a/a



ALKEM LABORATORIES LTD.

Regd. Office : ALKEM HOUSE, Senapati Bapat Marg,
Lower Parel (West), Mumbai - 400 013, Maharashtra, India.

- Phone: +91-22-3982 9999 • Fax: 022-2495 2955
- Email: contact@alkem.com • Website: www.alkemlabs.com
- CIN: L00305MH1973PLC174201

Press Release

Alkem reports Q2FY20 and H1FY20 Results

Mumbai, November 11, 2019: Alkem Laboratories Ltd (Alkem) today announced its standalone and consolidated financial results for the second quarter & six months ending September 30, 2019. These results were taken on record by the Board of Directors at a meeting held in Mumbai today.

Key financial highlights of Q2FY20

- Revenue from Operations was Rs.22,640 million, year-on-year growth of 18.0%
 - India sales were Rs.15,503 million, year-on-year growth of 17.6%
 - International sales were Rs.6,691 million, year-on-year growth of 15.2%
- Earnings before Interest, Tax, Depreciation and Amortization (EBITDA) was Rs.4,526 million, resulting in EBITDA margin of 20.0% vs. 19.0% in Q2FY19. EBITDA grew by 24.5% YoY
- R&D expenses for the quarter was Rs.1,234 million, or 5.5% of Revenue from Operations compared to Rs.1,049 million in Q2FY19 at 5.5% of Revenue from Operations
- Profit before tax (PBT) was Rs.4,099 million, a growth of 25.7% compared to Q2FY19
- Net Profit (after Minority Interest) was Rs.3,709 million, year-on-year growth of 45.7%

Key financial highlights of H1FY20

- Revenue from Operations was Rs.41,135 million, year-on-year growth of 15.0%
 - India sales were Rs.27,725 million, year-on-year growth of 15.1%
 - International sales were Rs.12,604 million, year-on-year growth of 11.7%
- Earnings before Interest, Tax, Depreciation and Amortization (EBITDA) was Rs.7,171 million, resulting in EBITDA margin of 17.4% vs. 15.9% in H1FY19. EBITDA grew by 26.4% YoY
- R&D expenses for H1FY20 was Rs.2,268 million, or 5.5% of Revenue from Operations compared to Rs.2,035 million in H1FY19 at 5.7% of Revenue from Operations
- Profit before tax (PBT) was Rs.6,199 million, a growth of 24.5% compared to H1FY19
- Net Profit (after Minority Interest) was Rs.5,563 million, year-on-year growth of 42.4%

Commenting on the results, Sandeep Singh, Managing Director, Alkem said, "Q2FY20 has been a strong quarter for the Company marked by robust growth across most of our key therapy segments in India and healthy growth in our International business. Our ongoing efforts towards cost optimisation and productivity improvement are yielding results with YoY improvement in EBITDA margins during the quarter and six months ending September 2019. We look forward to carry this momentum for the remaining part of the year as we leverage the investments we have made in our infrastructure, capabilities and our people over the last two years."



ALKEM LABORATORIES LTD.

Regd. Office : ALKEM HOUSE, Senapati Bapat Marg,
Lower Parel (West), Mumbai - 400 013, Maharashtra, India.

- Phone: +91-22-3982 9999 • Fax: 022-2495 2955
- Email: contact@alkem.com • Website: www.alkemlabs.com
- CIN: L00305MH1973PLC174201

Operational Highlights

India Business

In Q2FY20, the Company's India sales grew by 17.6% YoY, recording a sales of Rs.15,503 million as compared to Rs.13,184 million in Q2FY19. For H1FY20, the Company's India sales grew by 15.1% to Rs.27,725 million compared to Rs.24,091 million in H1FY19.

As per IQVIA data September 2019, during the quarter, the Company registered value growth of 23.5% YoY, outperforming the Indian Pharmaceutical Market (IPM) growth of 13.1% YoY. In the anti-infective segment, which is the largest therapy segment for the Company, Alkem grew significantly ahead of the market growth rate, thereby further consolidating its leadership position in the segment. Also in other large therapy segments like Gastro-Intestinal, Vitamins / Minerals / Nutrients, Neuro / CNS, Cardiac and Anti-Diabetes, the Company's growth rate was higher than the market growth rate leading to market share gains and improvement in market rankings. This outperformance was a result of Company's strong brands, effective sales and marketing strategies, robust supply chain and distribution network and contribution from new product launches.

The performance highlights in the key therapeutic segments in Q2FY20 and H1FY20 are as shown below:

Key Therapy segment	Q2FY20				H1FY20			
	Alkem Rank	YoY change in Rank*	YoY growth (Alkem)	YoY growth (IPM)	Alkem Rank	YoY change in Rank*	YoY growth (Alkem)	YoY growth (IPM)
Anti-infectives	1	Unchanged	30.8%	19.9%	1	Unchanged	26.9%	15.7%
Gastro Intestinal	3	Unchanged	17.5%	12.1%	3	Unchanged	17.5%	10.5%
Pain / Analgesics	3	Unchanged	17.1%	15.2%	3	Unchanged	15.1%	13.8%
Vitamins / Minerals / Nutrients	4	Unchanged	29.0%	13.3%	4	Unchanged	27.5%	12.8%
Neuro / CNS	6	+1	14.5%	9.8%	6	+2	14.2%	9.6%
Derma	13	+2	9.5%	9.6%	16	-1	6.9%	9.2%
Cardiac	26	Unchanged	26.4%	11.7%	26	Unchanged	26.8%	11.6%
Anti-Diabetic	21	+1	35.3%	13.2%	21	+1	35.9%	12.8%
Total	4	+1	23.5%	13.1%	5	+1	21.4%	11.9%

*Positive change in rank reflects improvement over same period previous year

Source: IQVIA September 2019

International Business

In Q2FY20, the Company's International sales grew by 15.2% YoY, recording sales of Rs.6,691 million as compared to Rs.5,809 million in Q2FY19. For H1FY20, the Company's International sales grew by 11.7% to Rs.12,604 million compared to Rs.11,288 million in H1FY19.

- **US sales** for the quarter was Rs.5,276 million, recording a year-on-year growth of 11.7%. For H1FY20, US sales was Rs.10,093 million, up 12.6% compared to H1FY19.



ALKEM LABORATORIES LTD.

Regd. Office : ALKEM HOUSE, Senapati Bapat Marg,
Lower Parel (West), Mumbai - 400 013, Maharashtra, India.

- Phone: +91-22-3982 9999 • Fax: 022-2495 2955
- Email: contact@alkem.com • Website: www.alkemlabs.com
- CIN: L00305MH1973PLC174201

- **Other International Markets sales** for the quarter was Rs.1,415 million, recording a year-on-year growth of 30.6%. For H1FY20, Other International Markets sales was Rs.2,511 million, up 7.9% compared to H1FY19.

R&D Investments

During the quarter, the Company filed 5 abbreviated new drug applications (ANDAs) with the US FDA and received 7 approvals (including 2 tentative approval). For H1FY20, the Company filed 7 ANDAs with the US FDA and received 12 approvals (including 4 tentative approval).

As on September 30, 2019, the Company has filed a total of 131 ANDAs and 1 new drug application (NDA) with the US FDA. Of these, it has received approvals for 77 ANDAs (including 11 tentative approvals) and 1 NDA.

Update on US FDA inspections

Facility	Capability	Last inspection	Status post last inspection
Baddi (India)	Formulation	August 2019	Successfully closed without any observations
Daman (India)	Formulation	August 2019	EIR# received in October 2019, thereby successfully closing the inspection
St. Louis (US)	Formulation	February – March 2019	Received Form 483 with 8 observations. Plant classified as OAI*
California (US)	API	August 2018	Successfully closed without any observations
Ankleshwar (India)	API	December 2016	EIR# received in March 2017, thereby successfully closing the inspection
Mandva (India)	API	September 2015	EIR# received in March 2016, thereby successfully closing the inspection

*OAI – Official Action Indicated

EIR – Establishment Inspection Report



ALKEM LABORATORIES LTD.

Regd. Office : ALKEM HOUSE, Senapati Bapat Marg,
Lower Parel (West), Mumbai - 400 013, Maharashtra, India.

- Phone: +91-22-3982 9999 • Fax: 022-2495 2955
- Email: contact@alkem.com • Website: www.alkemlabs.com
- CIN: L00305MH1973PLC174201

Q2FY20 and H1FY20 Conference Call at 5:00 pm IST, November 11, 2019

Alkem Laboratories Ltd. will organize a conference call for investors and analysts on Monday, November 11, 2019 at 5:00 pm IST to discuss its Q2FY20 and H1FY20 financial results.

Alkem Laboratories Ltd. will be represented on the call by Mr. Sandeep Singh, Managing Director and the senior management team.

Motilal Oswal Securities will host the call.

Details of the conference call are as under:

Time: 5:00 pm IST (GMT + 5:30) on Monday, November 11, 2019

Dial in Details:

India : +91 22 6280 1149 / +91 22 7115 8050

International Toll Free

USA : 1 866 746 2133

UK : 0 808 101 1573

Singapore : 800 101 2045

Hong Kong : 800 964 448

You are requested to dial in 10 mins ahead of the scheduled start time. A transcript of this conference call will also be available on our website www.alkemlabs.com

About Alkem Laboratories Ltd.

Established in 1973 and headquartered in Mumbai, Alkem (NSE: ALKEM, BSE: 539523, Bloomberg: ALKEM.IN, Reuters: ALKE.NS) is a leading Indian pharmaceutical company with global operations, engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products. The Company produces branded generics, generic drugs, active pharmaceutical ingredients (APIs) and nutraceuticals, which it markets in India and International markets. With a portfolio of more than 800 brands in India, Alkem is ranked the fifth largest pharmaceutical company in India in terms of domestic sales (Source: IQVIA MAT September 2019). The Company also has presence in more than 50 international markets, with the United States being its key focus market.

For more information on Alkem Laboratories Ltd., please visit www.alkemlabs.com

For further information or queries please contact

Gagan Borana

Investor Relations – Alkem Laboratories Ltd.

Tel: +91 22 3982 9960 / Mobile: +91 98190 56333

E-mail: gagan.borana@alkem.com



Alkem Laboratories Ltd.

Investor Presentation Q2FY20 – November 11, 2019

Safe Harbor Statement



This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions. Forward-looking statements are all statements that concern plans, objectives, goals, strategies, future events or performance and underlying assumptions and other statements that are other than statements of historical fact, including, but not limited to, those that are identified by the use of words such as “anticipates”, “believes”, “estimates”, “expects”, “intends”, “plans”, “predicts”, “projects” and similar expressions. Risks and uncertainties that could affect us include, without limitation:

- General economic and business conditions in India and other key global markets in which we operate;
- The ability to successfully implement our strategy, our research and development efforts, growth & expansion plans and technological changes;
- Changes in the value of the Rupee and other currency changes;
- Changes in the Indian and international interest rates;
- Allocations of funds by the Governments in our key global markets;
- Changes in laws and regulations that apply to our customers, suppliers, and the pharmaceutical industry;
- Increasing competition in and the conditions of our customers, suppliers and the pharmaceutical industry; and
- Changes in political conditions in India and in our key global markets.

Should one or more of such risks and uncertainties materialize, or should any underlying assumption prove incorrect, actual outcomes may vary materially from those indicated in the applicable forward-looking statements.

Any forward-looking statement or information contained in this presentation speaks only as of the date of the statement. We are not required to update any such statement or information to either reflect events or circumstances that occur after the date the statement or information is made or to account for unanticipated events, unless it is required by Law.



Key Highlights of Q2FY20 and H1FY20



- **Revenue from Operations** grew by 18.0% YoY during the quarter, accompanied by 100 bps YoY improvement in EBITDA margin
- **Profit After Tax** for the quarter grew by 45.7% compared to the previous year
- **India Business:** As per secondary sales data by IQVIA, the Company's secondary sales growth in Q2FY20 was 23.5% YoY – significantly higher than IPM growth of 13.1% YoY
 - The Company registered 30.8% YoY growth in the anti-infective segment during the quarter compared to therapy growth rate of 19.9% YoY (Source: IQVIA data)
- **US Business** grew in double digits during Q2FY20 and H1FY20, largely driven by new product launches and market share gain in existing products
- **R&D** expenses during the quarter was at 5.5% of revenue from operations
 - The Company has filed 7 ANDAs and received 12 ANDA approvals (including 4 tentative) from the US FDA in H1FY20
- **EIR for Daman and Baddi formulation facilities:** The Company received EIR of its manufacturing facilities located at Daman and Baddi which were inspected in the month of August 2019




Key Financial Highlights – Q2FY20 (Consolidated)




All figures in Rs mn


Revenue from Operations



India sales




International sales




Key Financial Highlights – Q2FY20 (Consolidated)

All figures in Rs mn


Gross Profit and Gross Margin




EBITDA and EBITDA Margin



PBT (before Minority Interest)



PAT (after Minority Interest)



Key Financial Highlights – H1FY20 (Consolidated)




Particulars (Rs mn)	H1FY20	H1FY19	YoY growth
Revenue from Operations	41,135	35,778	15.0%
Gross Profit	24,974	22,064	13.2%
Gross Profit margin	60.7%	61.7%	
EBITDA	7,171	5,674	26.4%
EBITDA margin	17.4%	15.9%	
PBT	6,199	4,978	24.5%
PBT margin	15.1%	13.9%	
PAT (After Minority Interest)	5,563	3,906	42.4%
PAT margin	13.5%	10.9%	
EPS (Rs / share)	46.53	32.67	




India Business: Q2FY20 Sales of Rs.15,503 million (17.6% YoY growth)

- India sales contributed 69.9% to total sales in Q2FY20
- In Q2FY20, Company's secondary sales grew by 23.5% YoY - significantly ahead of the IPM growth of 13.1% YoY. Similarly in H1FY20 also, the Company grew ahead of the IPM with growth of 21.4% compared IPM growth of 11.9% (Source: IQVIA data)
- As a result of this outperformance, for the quarter ended September 2019, Alkem gained one rank and featured amongst the top four pharmaceutical companies in India (Source: IQVIA data)
- This outperformance was largely led by Anti-Infectives segment where the Company continues to maintain its leadership position (Source: IQVIA data)
- During the quarter, the Company also improved its ranking in the chronic therapy segments like Neuro / CNS, Derma and Anti-Diabetes (Source: IQVIA data)

Q2FY20 – India Sales (Rs mn)



H1FY20 – India Sales (Rs mn)




India Business – Secondary Sales Performance




Outperformance across most of the major therapeutic areas in Q2FY20

Established therapeutic areas of Alkem



Emerging therapeutic areas of Alkem




Source: IQVIA data ¹ Domestic formulations sales; ² For 3 months ended September 30, 2019


US Business: Q2FY20 Sales of Rs.5,276 million (11.7% growth YoY)

- US sales contributed 23.8% to total sales in Q2FY20
- In Q2FY20, the Company filed 5 ANDAs with the US FDA and received 7 approvals (including 2 tentative approval)
- As on September 30, 2019, the Company has filed a total of 132 ANDAs (including 1 NDA) with the US FDA and has received 78 approvals (including 11 tentative approvals and 1 NDA)
- Recently, the Company received EIR for its formulation manufacturing facilities at Daman and Baddi (India) which were inspected in August 2019

Q2FY20 – US Sales (Rs mn)



H1FY20 – US Sales (Rs mn)



Update on the US FDA inspection



Facility	Scope	Last inspection	Status post last inspection
Baddi (India)	Formulation	August 2019	Successfully closed without any observations
Daman (India)	Formulation	August 2019	EIR# received in October 2019, thereby successfully closing the inspection
St. Louis (US)	Formulation	February - March 2019	Received Form 483 with 8 observations. Plant classified as OAI*
California (US)	API	August 2018	Successfully closed without any observations
Ankleshwar (India)	API	December 2016	EIR# received in March 2017, thereby successfully closing the inspection
Mandva (India)	API	September 2015	EIR# received in March 2016, thereby successfully closing the inspection

*OAI – Official Action Indicated

EIR – Establishment Inspection Report




Other International Business


Other International Business: Q2FY20 Sales of Rs.1,415 million (30.6% growth YoY)

- Other International Market sales contributed 6.4% to total sales in Q2FY20
- The Company has presence in Australia, Europe, South East Asia, Latin America and Africa
- Australia, Chile, Kazakhstan and Europe registered healthy YoY growth during the quarter

**Q2FY20 – Other International Sales
(Rs mn)**




**H1FY20 – Other International Sales
(Rs mn)**



Latest Shareholding Pattern



Shareholding pattern as on September 30, 2019



Institution – Mutual Funds, Alternate Investment Funds, Foreign Portfolio Investors, Financial Institutions / Banks

Non-Institution – Public, Other Bodies Corporates, Clearing Members, Non Resident Indians, Hindu Undivided Family and Trusts



Thank You

